Evidence map›Paper›PMID 40345181›Full record

Trial reportCell reports. Medicine2025

The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy.

David J Park, Min Thura, Vi K Chiu, Brian Vicuna, Koon Hwee Ang, Blanca Sanchez, Pei Ling Chia, Kam Yew Kuan, Jie Li, Ke Zhang and 3 more

Registry-linked trialAbstract readMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07290088 (An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumor Patients), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07290088 phase2 / phase3recruitingnot on this map

An Open Label, Multicenter, Safety and Efficacy Phase II/III Study of PRL3-Zumab in Solid Tumor Patients

TypeinterventionalSponsorIntra-IMMUSG Pte LtdRan2023 to 2026Enrolled52ConditionsAdvanced Solid CancersArmsPRL3-ZUMAB
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

David J ParkSt Jude Crosson Cancer Institute/ Providence Medical Foundation, St. Jude Heritage Medical Group, Fullerton, CA, USA.
Min ThuraInstitute of Molecular and Cell Biology (IMCB), Agency for Science Technology and Research (A∗STAR), 61 boipolis drive, Singapore 138673, Singapore. Electronic address: mthura@imcb.a-star.edu.sg.
Vi K ChiuThe Angeles Clinic & Research Institute, a Cedars-Sinai affiliate, Santa Monica, CA, USA.
Brian VicunaComprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA.
Koon Hwee AngInstitute of Molecular and Cell Biology (IMCB), Agency for Science Technology and Research (A∗STAR), 61 boipolis drive, Singapore 138673, Singapore.
Blanca SanchezSt Jude Crosson Cancer Institute/ Providence Medical Foundation, St. Jude Heritage Medical Group, Fullerton, CA, USA.
Pei Ling ChiaInstitute of Molecular and Cell Biology (IMCB), Agency for Science Technology and Research (A∗STAR), 61 boipolis drive, Singapore 138673, Singapore.
Kam Yew KuanInstitute of Molecular and Cell Biology (IMCB), Agency for Science Technology and Research (A∗STAR), 61 boipolis drive, Singapore 138673, Singapore.
Jie LiInstitute of Molecular and Cell Biology (IMCB), Agency for Science Technology and Research (A∗STAR), 61 boipolis drive, Singapore 138673, Singapore.
Ke ZhangInstitute of Molecular and Cell Biology (IMCB), Agency for Science Technology and Research (A∗STAR), 61 boipolis drive, Singapore 138673, Singapore; Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China.
Wei Hui ZhengInstitute of Molecular and Cell Biology (IMCB), Agency for Science Technology and Research (A∗STAR), 61 boipolis drive, Singapore 138673, Singapore; Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine, Hangzhou, Zhejiang, China.
Matthew Chau Hsien NgDepartment of GI Oncology, National Cancer Centre Singapore, Singapore, Singapore; Duke-NUS School of Medicine, Singapore, Singapore.
Qi ZengInstitute of Molecular and Cell Biology (IMCB), Agency for Science Technology and Research (A∗STAR), 61 boipolis drive, Singapore 138673, Singapore; The Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119260, Singapore; The INTRA-IMMUSG PTE LTD, Singapore, Singapore. Electronic address: mcbzengq@imcb.a-star.edu.sg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This Food and Drug Administration (FDA)-approved phase 2 basket trial has three highlights: (1) PRL3, an intracellular oncotarget that is highly (∼80.6%) expressed in multiple cancers; (2) PRL3-zumab, the first-in-class humanized antibody (immunoglobulin G1 [IgG1]) with high affinity to PRL3 (K

Indexed as

Antibodies, Monoclonal, HumanizedImmunotherapyNeoplasm ProteinsNeoplasmsProtein Tyrosine PhosphatasesAdultAgedFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedNeoplasm ProteinsProtein Tyrosine PhosphatasesPTP4A3 protein, humanEES setefficacy evaluable set,FAS setfull analysis set,historical dataintracellular oncoproteinintra-patient comparisonPFSphase 2 basket clinical trialPRL3PRL3-zumabSEPSCsingle evaluable patient single cohort,

Identifiers

PMID40345181
PMCPMC12147911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.